metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-111 FREQUENCY OF LIVER STEATOSIS AND FIBROSIS DETERMINED BY FIBROSCAN AND CAP ...
Información de la revista
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 24. Núm. S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(septiembre 2021)
Open Access
P-111 FREQUENCY OF LIVER STEATOSIS AND FIBROSIS DETERMINED BY FIBROSCAN AND CAP IN A SCREENING PROGRAM
Visitas
563
Pedro Montes Teves1, Rocío Galloso Gentille2, Diego Rosales Ruiz1, Flor Beltran Valdivia3, Claudia Mori Torres4, Vanessa Valenzuela Granados5, Flor Araujo León4, Cecilia Cabrera Cabrejos6, Bertha Cárdenas Ramírez6, Jaime Fustamante Flores1, Roxana Gallegos López7, Carlos García-Encinas5, Carlos Nureña Flores8, Rossana Ráez León9, Rocío Ramos Miraval9, Briny Rodríguez Vargas1, Julio Santiago Marcelo10, Stefanie Salazar Rivas3, Sonia Salazar Ventura1, María Grazia Venturelli Romero6
1 Hospital Nacional Daniel A. Carrión – Callao
2 Hospital San José – Callao
3 Hospital Central de la Policía Nacional del Perú
4 Hospital Nacional Alberto Sabogal
5 Hospital Cayetano Heredia
6 Hospital Nacional Guillermo Almenara Irigoyen
7 Hospital Nacional María Auxiliadora
8 Hospital Nacional 2 de Mayo
9 Hospital Centro Médico Naval Cirujano Mayor Santiago Távara
10 Hospital Emergencias Villa El Salvador
Ver más
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 24. Núm S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

Más datos
Introduction

Nonalcoholic fatty liver disease represents a worldwide public health problem, in Latin America a prevalence of around 30% is estimated, however in Peru we do not have large epidemiological studies about this.

Objectives

To evaluate the frequency of liver steatosis determined by CAP (Controlled Attenuation Parameter) and liver fibrosis by hepatic elastography in a population of patients who participated in a screening campaign.

Material and Methods

Descriptive and cross-sectional study. During the period September-December 2019, the ALEH Screening Fibroscan program was carried out in 4 reference hospitals in Lima and Callao. Patients were evaluated with a Fibroscan 530 device with M and XL probes. Those examinations that met the quality parameters were included for the study: 10 valid measurements, IQR <30% for liver stiffness, IQR <40 dB / m for CAP. The study population was people aged 18 and older who voluntarily attended the screening campaigns.

Results

1978 patients were included, with an average age of 54.22 +/- 14.36 years, the distribution by sex was 1342 women (67.8%) and 636 men (32.2%). The distribution according to the degree of liver steatosis determined by CAP was S0: 1198 (60.6%), S1: 335 (16.9%), S2: 59 (3%), S3: 386 (19.5%). The distribution according to the degree of fibrosis was F0-1: 1662 (84%), F2: 97 (4.9%), F3: 98 (5%), F4: 121 (6.1%).

Conclusions

In the studied population a frequency of hepatic steatosis of 39.4% and advanced hepatic fibrosis of 11.1% was found.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos